World's Best Scientists 2026 revealed!
George K. K. Lau

George K. K. Lau

D-Index & Metrics

Medicine

D-Index
86
Citations
38566
World Ranking
13896
National Ranking
157

Overview

George K. K. Lau is affiliated with Humanity & Health in China and has contributed extensively to the field of medicine, particularly within the subfields of hepatology, epidemiology, oncology, infectious diseases, and surgery. Their research portfolio includes over two hundred publications, reflecting a focus on liver diseases, viral hepatitis, cancer, and infectious disease dynamics.

The scientist's work encompasses key topics such as liver disease diagnosis and treatment, liver disease and transplantation, hepatocellular carcinoma treatment and prognosis, hepatitis C virus research, COVID-19 clinical research studies, hepatitis B virus studies, and cancer immunotherapy and biomarkers.

Notable recent papers authored or co-authored by George K. K. Lau include:

  • Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma, 2022, NEJM Evidence
  • Prediction for Progression Risk in Patients With COVID-19 Pneumonia: The CALL Score, 2020, Clinical Infectious Diseases
  • Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study, 2020, Journal of Hepatology
  • COVID-19: Discovery, diagnostics and drug development, 2020, Journal of Hepatology
  • Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA., 2022, Journal of Clinical Oncology

Frequent co-authors collaborating with George K. K. Lau include Shiv Kumar Sarin, Saeed Hamid, Diana A. Payawal, Ashok Choudhury, and Sombat Treeprasertsuk. These collaborations have yielded significant research output across several medical journals focused on hepatology and oncology.

The scientist's publications predominantly appear in specific journals known for hepatology and oncology research. The leading venues featuring their work are Hepatology International, Journal of Hepatology, Annals of Oncology, Journal of Clinical Oncology, and Gastroenterology.

Their research contributions cover a spectrum of clinical and translational medicine topics within liver diseases and cancer, integrating both clinical studies and therapeutic advancements. The interplay between liver disease and infectious agents, notably COVID-19 and viral hepatitis, forms a significant portion of their research activities.

Best Publications

  • Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.

    S. K. Sarin;M. Kumar;G. K. Lau;Z. Abbas

  • Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B

    George K.K. Lau;Teerha Piratvisuth;Kang Xian Luo;Patrick Marcellin

  • Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

    Yun-Fan Liaw;Nancy H. L. Leung;Jia-Horng Kao;Teerha Piratvisuth

  • Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B

    Patrick Marcellin;George K.K. Lau;Ferruccio Bonino;Patrizia Farci

  • Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL)

    Shiv Kumar Sarin;Ashish Kumar;John A. Almeida;Yogesh Kumar Chawla

  • Persistence of cccDNA During the Natural History of Chronic Hepatitis B and Decline During Adefovir Dipivoxil Therapy

    Bettina Werle-Lapostolle;Scott Bowden;Stephen Locarnini;Karsten Wursthorn;Karsten Wursthorn

  • Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use

    Kam Chuen Lai;Shiu Kum Lam;Kent Man Chu;Benjamin C Y Wong

  • Silver nanoparticles inhibit hepatitis B virus replication.

    Lei Lu;Raymond Wai-Yin Sun;Rong Chen;Chee-Kin Hui

  • Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa‐2a in HBeAg‐negative chronic hepatitis B

    Maurizia Rossana Brunetto;Francesco Moriconi;Ferruccio Bonino;George K. K. Lau

  • Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update.

    Yun-Fan Liaw;Nancy Leung;Richard Guan;George K.K. Lau

  • Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary.

    Geoffrey C Farrell;Shivakumar Chitturi;George K K Lau;José D Sollano

  • Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy.

    Chee–Kin Hui;Winnie W.W. Cheung;Hai–Ying Zhang;Wing–Yan Au

  • Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy

    George K.K Lau;Harry H.Y Yiu;Daniel Y.T Fong;Hoi-Ching Cheng

  • Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers

    Alexander J.V. Thompson;Tin Nguyen;David Iser;David Iser;Anna Ayres

  • Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients.

    Zheng Zhang;Hu Lin;Ming Shi;Ruonan Xu

  • Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.

    Erik H.C.J. Buster;Bettina E. Hansen;George K.K. Lau;Teerha Piratvisuth

  • COVID-19: Discovery, diagnostics and drug development.

    Tarik Asselah;David Durantel;Eric Pasmant;George Lau

  • Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a

    Patrick Marcellin;Ferruccio Bonino;George K.K. Lau;Patrizia Farci

  • Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines.

    Shivakumar Chitturi;Geoffrey C Farrell;Etsuko Hashimoto;Toshiji Saibara

  • MINIMUM GRAFT SIZE FOR SUCCESSFUL LIVING DONOR LIVER TRANSPLANTATION

    Chung-mau Lo;Sheung-tat Fan;Chi-leung Liu;John K. Chan

Frequent Co-Authors

Shiv Kumar Sarin
Shiv Kumar Sarin Institute of Liver and Biliary Sciences
Stephen Locarnini
Stephen Locarnini Melbourne Health
Sheung Tat Fan
Sheung Tat Fan University of Hong Kong
Chung Mau Lo
Chung Mau Lo University of Hong Kong
Sharon R. Lewin
Sharon R. Lewin University of Melbourne
Osamu Yokosuka
Osamu Yokosuka Chiba University
Ching-Lung Lai
Ching-Lung Lai University of Hong Kong
Man-Fung Yuen
Man-Fung Yuen University of Hong Kong
Patrick Marcellin
Patrick Marcellin Université Paris Cité
Ferruccio Bonino
Ferruccio Bonino National Research Council (CNR)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medical careers in the USA opens up a variety of online degree options for students with different goals. For those who wish to enter the healthcare field rapidly, you might be interested in learning what is the fastest way to become an lpn. Licensed Practical Nurse (LPN) programs can be completed quickly, allowing graduates to start working in patient care settings sooner.

If you want to specialize, you may consider advanced nursing. For example, there are options for the fastest pmhnp program, which allows nurses to become Psychiatric Mental Health Nurse Practitioners through accelerated online degrees.

For those drawn to the management side of healthcare, you can find healthcare administration degrees that cover essential leadership, policy, and business skills. Those looking for an advanced credential in this area might explore affordable online mha programs, which help professionals move into executive roles.

With online education, you can access flexible, affordable pathways toward fulfilling healthcare careers beyond the traditional route to a medical degree.

Best Scientists Citing George K. K. Lau

Trending Scientists